This oral delivery technology is built around a bioadhesive/mucoadhesive dextrin excipient beta-limit dextrin (BLD) which is manufactured by treating starch (amylopectin) with beta-amylase. The excipient is mixed with an active pharmaceutical ingredient (API) and freeze-dried to make 'wafers'. In the mouth, these lyophilised wafers deliver the API(s) through the mucosa into the blood stream. This is a rapidly growing area of drug delivery with many physiological advantages over other modes of delivery, e.g. misses first hepatic pass; speed of activity; ease of use; choke free risk of use (unlike tablets); suitable for infirm, infant and elderly users and; desirable sensory properties. The system also provides flexibility in terms of loading low and high therapeutic doses, flavours, colours, shapes etc. Different drugs (and active agents) can be delivered through the buccal mucosa using this technology. Trials have confirmed the efficacy of the technology (physical properties in the mouth and absorption through the mucosa of the mouth) in both animals (different species) and man.


Resource 1 - A Chemical Carrier Based on Beta-limit Dextrin

Resource 2 - β-Limit dextrin – a new food and pharmaceutical resource

Resource 3 - Rapid method to determine the molecular weight of dextrins and dextrans

Resource 4 - Use of carbohydrates, including dextrins, for oral delivery

Resource 5 - Bioadhesive properties of β-limit dextrin

Resource 6 - β-limit Dextrin – Properties and applications

Resource 7 - Applications of β-limit dextrin as a matrix forming excipient for fast disintegrating buccal dosage formats

Resource 8 - Pharmaceutical applications of starch and starch derivatives – A mini review


What's new?

Trials are under development for new drugs to be delivered in the buccal format.